Rivastigmine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Rivastigmine is a cholinesterase inhibitor used for dementia due to Alzheimer disease and Parkinson disease. It is available as oral capsules/solution and as a transdermal patch, with the patch often improving gastrointestinal tolerability. Key safety concerns include nausea, vomiting, weight loss, bradycardia, syncope, falls, and application-site allergic contact dermatitis.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Rivastigmine is a cholinesterase inhibitor used for dementia due to Alzheimer disease and Parkinson disease. NutriStack rates the supporting evidence as strong. Common adult dosing is Oral capsules often start at 1.5 mg twice daily with food and titrate every 2 weeks as tolerated to 3-6 mg twice daily. Patch starts at 4.6 mg/24 hours once daily, then titrates to 9.5 mg/24 hours and, when appropriate, 13.3 mg/24 hours., though a prescriber sets the actual dose. This profile indexes 3 sources.
The bottom line
Evidence rating strong. Most-documented uses: symptomatic treatment of mild to moderate alzheimer disease dementia, symptomatic treatment of dementia associated with parkinson disease, severe alzheimer disease treatment with higher-dose patch in labeled use. 3 sources indexed (2004–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine availability in cortical and subcortical cholinergic pathways affected by neurodegenerative disease. Enhanced cholinergic signaling may modestly improve or stabilize cognition and function in some patients. Peripheral cholinergic effects explain gastrointestinal adverse effects, bradycardia, syncope, bronchospasm risk, urinary effects, and possible seizure-threshold concerns.2,3
Dosing & protocol.
Oral rivastigmine should be taken with meals. The patch is applied once daily to clean, dry, hairless skin and rotated to reduce skin reactions.
Full safety detail.
Side effects
- Nausea
- Vomiting
- Diarrhea
- Anorexia
- Weight loss
- Dizziness
- Bradycardia
- Syncope
- Falls
- Tremor worsening in Parkinson disease
- Application-site reactions
- Allergic contact dermatitis
- GI bleeding risk in susceptible patients
Contraindications
- Hypersensitivity to rivastigmine, other carbamate derivatives, or formulation components2,3
- History of application-site reaction with rivastigmine patch suggestive of allergic contact dermatitis
- Use caution with sick sinus syndrome, conduction disease, active peptic ulcer disease, asthma or COPD, seizure history, or low body weight3
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1Cholinesterase inhibitors for Alzheimer's diseaseBirks J · Cochrane Database of Systematic Reviews · 2006
Systematic review found symptomatic cognitive and functional benefits with common gastrointestinal adverse effects.
Randomized controlled trials
1- 2Rivastigmine for dementia associated with Parkinson's diseaseEmre M et al. · New England Journal of Medicine · 2004
Trial supported rivastigmine benefit in Parkinson disease dementia, with cholinergic adverse effects.
Reference material
1- 3RIVASTIGMINE transdermal system, US Prescribing InformationURLU.S. National Library of Medicine · DailyMed · 2026
Labeling describes patch dosing, contraindication after allergic contact dermatitis, GI adverse effects, weight loss, and bradycardia cautions.
Common questions.
Quick answers about Rivastigmine, drawn from the data on this page.
What is Rivastigmine?
Rivastigmine is a cholinesterase inhibitor used for dementia due to Alzheimer disease and Parkinson disease. It is available as oral capsules/solution and as a transdermal patch, with the patch often improving gastrointestinal tolerability. Key safety concerns include nausea, vomiting, weight loss, bradycardia, syncope, falls, and application-site allergic contact dermatitis.
What is Rivastigmine used for?
Commonly cited benefits of Rivastigmine include: Symptomatic treatment of mild to moderate Alzheimer disease dementia; Symptomatic treatment of dementia associated with Parkinson disease; Severe Alzheimer disease treatment with higher-dose patch in labeled use. NutriStack rates the overall evidence as strong.
What is a typical dose of Rivastigmine?
A typical adult dose of Rivastigmine is Oral capsules often start at 1.5 mg twice daily with food and titrate every 2 weeks as tolerated to 3-6 mg twice daily. Patch starts at 4.6 mg/24 hours once daily, then titrates to 9.5 mg/24 hours and, when appropriate, 13.3 mg/24 hours.. The commonly recommended form is Transdermal patch for many patients because of steadier exposure and less gastrointestinal intolerance; oral capsule or solution when appropriate. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Rivastigmine?
Reported side effects include nausea, vomiting, diarrhea, anorexia, weight loss, dizziness. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Rivastigmine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Rivastigmine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.